TTK

Across TCGA pan-cancer cohorts, TTK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTK data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTK expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where TTK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.898	0.387	.005	17	view →
LSCC	DFS	Median	All	0.811	0.617	.013	13	view →
HNSC	OS	Tertile	III,IV	0.797	0.518	.023	12	view →
LUAD	OS	Tertile	II,III,IV	0.396	0.807	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTK–PDAC (OS)

Open the PDAC breakdown →